Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Rating Reaffirmed by Lifesci Capital

Perspective Therapeutics (NYSEAMERICAN:CATX)‘s stock had its “outperform” rating restated by stock analysts at Lifesci Capital in a research note issued on Monday, Zacks.com reports. Lifesci Capital also issued estimates for Perspective Therapeutics’ FY2024 earnings at ($0.12) EPS and FY2025 earnings at ($0.14) EPS.

A number of other equities analysts have also recently weighed in on the stock. Oppenheimer reissued an “outperform” rating and issued a $1.50 price objective (up from $1.20) on shares of Perspective Therapeutics in a research report on Monday, April 1st. B. Riley raised their price objective on Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a research note on Tuesday, April 9th.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at 1.76 on Monday. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.02. Perspective Therapeutics has a 52 week low of 0.21 and a 52 week high of 1.90. The firm has a market capitalization of $1.03 billion, a PE ratio of -17.60 and a beta of 1.43.

Insiders Place Their Bets

In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of Perspective Therapeutics stock in a transaction that occurred on Wednesday, March 6th. The stock was acquired at an average price of 0.95 per share, with a total value of 57,409,487.05. Following the completion of the acquisition, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately 110,934,724.30. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 3.52% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Bleakley Financial Group LLC purchased a new position in Perspective Therapeutics in the 1st quarter worth about $40,000. RIA Advisory Group LLC increased its position in shares of Perspective Therapeutics by 1,313.4% in the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock worth $127,000 after acquiring an additional 99,293 shares in the last quarter. ZWJ Investment Counsel Inc. acquired a new stake in shares of Perspective Therapeutics during the first quarter valued at approximately $26,000. Simplicity Wealth LLC purchased a new stake in shares of Perspective Therapeutics in the 1st quarter valued at approximately $40,000. Finally, Taylor & Morgan Wealth Management LLC boosted its stake in Perspective Therapeutics by 8.7% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after purchasing an additional 50,000 shares during the period. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.